- PDUFA goal date set for September 8, 2022
NASHVILLE, Tenn., April 21, 2022--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.
The FDA designated the BLA as a Class 2 resubmission, which has a six-month review period and includes a required reinspection of the company’s manufacturing facility. Revance was provided a Prescription Drug User Fee Act (PDUFA) goal date of September 8, 2022.
Revance is a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation, long-acting neuromodulator product, DaxibotulinumtoxinA for Injection. Revance has successfully completed Phase 3 clinical programs for DaxibotulinumtoxinA for Injection in glabellar (frown) lines, for which the company is currently pursuing U.S. regulatory approval, and in cervical dystonia. Revance is also evaluating DaxibotulinumtoxinA for Injection in adult upper limb spasticity. Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the OPUL™ Relational Commerce Platform. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which if approved, would be the first and only generic biosimilar to Botox® and Botox® Cosmetic. For more information or to join our team visit us at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered trademark of Allergan, Inc.
Any statements in this press release that are not statements of historical fact, including statements related to the anticipated approval, expected review period and PDUFA goal date of DaxibotulinumtoxinA for Injection in glabellar lines; expected reinspection of our facility by the FDA and our development of a biosimilar to BOTOX® with our partner, Viatris constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements will ever be achieved or occur.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties relate, but are not limited to: the results, timing, costs, and completion of our research and development activities and regulatory approvals, our ability to remediate deficiencies identified by the FDA and obtain FDA approval of the BLA for DaxibotulinumtoxinA for Injection for glabellar lines, including as a result of observations made by the FDA during the site inspection or other reasons; our ability to obtain funding for our operations; the timing of capital expenditures; the accuracy of our estimates regarding expenses, future revenues, capital requirements, our financial performance and the economics of DaxibotulinumtoxinA for Injection, the RHA® Collection of dermal fillers and OPUL™; the impact of the COVID-19 pandemic on our manufacturing operations, supply chain, end user demand for our products and services, the aesthetics market, commercialization efforts, business operations, regulatory meetings, inspections and approvals, clinical trials and other aspects of our business and on the market; our ability and the ability of our partners to manufacture supplies for our product candidates and to acquire supplies of the RHA® Collection of dermal fillers; the uncertain clinical development process, the risk that clinical trials may not have an effective design or generate positive results or that positive results would assure regulatory approval or commercial success; the applicability of clinical study results to actual outcomes; the rate and degree of economic benefit, safety, efficacy, commercial acceptance, market, competition and/or size and growth potential of the RHA® Collection of dermal fillers, OPUL™ and our drug product candidates, if approved; our ability to continue to successfully commercialize the RHA® Collection of dermal fillers and OPUL™ and our ability to successfully commercialize DaxibotulinumtoxinA for Injection, if approved, and the timing and cost of commercialization activities; the proper training and administration of our products by physicians and medical staff; our ability to expand sales and marketing capabilities; the status of commercial collaborations; changes in and failures to comply with privacy and data protection laws; our ability to effectively manage our expanded operations in connection with the acquisition of Hint, Inc; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; the cost and our ability to defend ourselves in product liability, intellectual property, class action or other lawsuits; the volatility of our stock price; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in our periodic filings with the Securities and Exchange Commission (SEC), including factors described in the section entitled "Risks Factors" on our Form 10-K, filed with the SEC on February 28, 2022. The forward-looking statements in this press release speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421006042/en/
Investors Revance Therapeutics, Inc.: Jessica Serra, 626-589-1007 Jessica.serra@revance.com or Gilmartin Group, LLC.: Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476 sfahy@revance.com
FDA Approves Innovative, Targeted Treatment
NRx Pharmaceuticals Inc (NASDAQ: NRXP) has filed a new Breakthrough Therapy designation request with the FDA for Zyesami focused on a subgroup of critical COVID-19 patients. The subgroup includes patients who were also treated with Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) in addition to aviptadil or placebo. The request includes safety data on approximately 750 patients treated with intravenous Zyesami for Critical COVID-19. NRx Pharmaceuticals submitted a Breakthrough Therapy d
The company's better-than-expected results couldn't counter management's cautious forecast.
Stocks end sharply lower Friday, a day after hawkish comments by the head of the U.S. central bank, as investors also weigh some disappointing corporate earnings.
The ongoing game of footsie between billionaire tech mogul Elon Musk and social media platform Twitter reached a new stage April 22, as Musk began major steps towards buying the company. It all began when Musk announced that he had acquired a 9.2% stake in Twitter, making him the company's largest shareholder at the time. The ensuing chaos was primarily orchestrated by Musk and his very visible presence on Twitter, where he has 82.9 million followers.
Nio (NYSE: NIO) stock plunged this week and had fallen 12.4% in five days as of 2 p.m. ET Friday, according to data provided by S&P Global Market Intelligence. There weren't many updates from Nio this week, but the few that there were could have driven shares of the electric vehicle (EV) manufacturer higher, if not for concerning news from China. Nio shares took a deep dive last week after the company said it had suspended operations in China to adhere to the COVID-19 lockdown rules.
Invesco Global Market Strategist Brian Levitt joins Yahoo Finance Live to discuss the latest statements from the Fed regarding interest rate hikes, volatility, shifting consumer demands throughout the pandemic, and the outlook on markets and tech stocks.
Approaching mid-year, we can see a clear shape developing for the markets in 2022, one based on increased volatility. The economy as a whole is facing challenges, in the form of inflation, a Fed policy shift, and continuing ripple effects from Russia’s Ukraine war and lingering COVID outbreaks, and investors are looking for pathways through it all. One clear path is to find the beaten-down stocks with potential for near- to mid-term outperformance. These are equities that have underperformed rec
In this article, we discuss 10 tech stocks that analysts are increasing the price targets of. If you want to see some more tech stocks that were favored by market experts recently, click Analysts Are Increasing Prices Targets of These 5 Tech Stocks. The COVID-19 pandemic propelled the technology sector into overdrive, in terms of […]
Meta Chief Operating Officer Sheryl Sandberg is now facing "internal scrutiny" at the company after pressuring U.K. tabloid the Daily Mail to kill a story about her former boyfriend, Activision Blizzard CEO Bobby Kotick. The revelations come in an explosive new report from the Wall Street Journal detailing a coordinated campaign to discourage the tabloid from publishing the story, pulling resources from both Activision Blizzard and Meta. In spite of denying that he had knowledge of disturbing allegations of employee misconduct, including alleged rape, Kotick apparently knew about many of those incidents — a fact he concealed from the company's board.
Irrational exuberance is alive and well on Wall Street, according to a valuation model proposed by former Federal Reserve Chairman Alan Greenspan. The story of how Greenspan came to use the phrase “irrational exuberance” is well-known and widely repeated: He first used it in a December 1996 speech, after listening to Yale University professor Robert Shiller give a lecture on the subject. Shiller reportedly based his comments on the Cyclically-Adjusted Price/Earnings ratio, or CAPE.
The latest tumble in stocks is, in many ways, a replay of what investors have seen with the Dow Jones Industrial Average (DJIA) the S&P 500 (SPX) and Nasdaq Composite (COMP) in recent months — another major disruption to global stock markets. U.S. stock markets are sharply down on Friday. The latest stock-market turmoil has come as markets have attempted to recalibrate amid policy changes at the Federal Reserve, record-high levels of inflation.
The company is far away from a recovery
Shares of Alibaba (NYSE: BABA) were up as much as 5.5% today, before settling into a 0.8% gain as of 1:56 p.m. ET. Yesterday, China's Securities Regulatory Commission held a meeting with members of large banks, insurance companies, and the country's social security fund, and encouraged these large in-country investors to buy stocks. China's government hasn't done itself any favors, of course.
The dire warning Rivian's CEO gave could have long-term implications on the company's prospects.
Stocks aren't like children -- it's OK to talk publicly about which investments are your favorites. I own shares of more than 60 different companies, but Disney (NYSE: DIS), Costco (NASDAQ: COST), and FuboTV (NYSE: FUBO) are my three favorite stocks right now.
Investors in steel giant Nucor (NYSE: NUE) had a great day on Thursday, with the stock exploding as much as 11% higher before succumbing to selling pressure on a red day for the markets, and ending with just a 3.7% gain. Indeed, with its 6.5% loss as of 11:50 a.m. ET this morning, Nucor stock has been dragged down below where it traded before reporting its earnings beat yesterday. Nucor beat earnings yesterday.
It is the biggest acquisition financing ever put forward for one person. Elon Musk is doing it his way. More than two-thirds of the $46.5 billion financing package that Musk unveiled on Thursday in support of his bid for Twitter Inc would come from his assets, with the remainder coming from bank loans secured against the social media platform's assets.
U.S. stocks plummeted Friday afternoon to close out another week in the red as investors weighed a bevy of corporate earnings and braced for more aggressive monetary tightening by the Federal Reserve in coming months.
Yahoo Finance Live's Julie Hyman and Brian Sozzi discuss first quarter earnings for oil services company Schlumberger.